DJ Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 0.69 euros per share to the Annual Shareholders' Meeting
Sartorius Stedim Biotech SA / Key word(s): Dividend/AGM/EGM
Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 0.69 euros per share to the Annual
Shareholders' Meeting
07-Feb-2024 / 17:30 CET/CEST
=----------------------------------------------------------------------------------------------------------------------
Aubagne, February 7, 2024
Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 0.69 euros per share to the Annual
Shareholders' Meeting
The Board of Directors of Sartorius Stedim Biotech S.A. resolved at today's meeting to submit a proposal to the
combined Annual Shareholders' Meeting to be held on March 26, 2024, to pay a dividend of 0.69 euros per share for
fiscal 2023. Under this proposal, the total distributed profit would be 67.1 million euros. The dividend will be paid
on April 4, 2024.
The Board of Directors also approved the decision to submit to the Annual Shareholders' Meeting the 2023 results of
Sartorius Stedim Biotech which had already been published on a preliminary basis on January 26, 2024.
This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech
Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could
cause actual results to differ materially from those expressed or implied by such statements. Sartorius Stedim Biotech
assumes no liability for updating such statements in light of new information or future events. Sartorius Stedim
Biotech shall not assume any liability for the correctness of this release. The original French press release is the
legally binding version.
Financial calendar
February 16, 2024 Publication of the 2023 Annual Report
March 26, 2024 Annual General Meeting
April 18, 2024 Publication of the quarterly figures January to March 2024
July 19, 2024 Publication of the half-year figures January to June 2024
October 17, 2024 Publication of the nine-month figures January to September 2024
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of
innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications,
such as cell and gene therapies, safely, rapidly, and economically. The shares of Sartorius Stedim Biotech S.A. are
quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales
entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through
acquisitions of complementary technologies. In 2023, the company generated sales revenue of around 2.8 billion euros,
according to preliminary figures. Currently, more than 10,600 employees are working for customers around the globe.
Contact
Timo Lindemann
External Communications
+49 (0)551.308.4724
timo.lindemann@sartorius.com
=----------------------------------------------------------------------------------------------------------------------
Attachment
File: Media Release
=----------------------------------------------------------------------------------------------------------------------
Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Language: English
Issuer: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone: +33 44 284 5600
E-mail: sartorius.presse@sartorius.com
Internet: www.sartorius-stedim.com
ISIN: FR0013154002
EQS News ID: 1832769
End of Announcement - EQS News Service
=------------------------------------------------------------------------------------
1832769 07-Feb-2024 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1832769&application_name=news
(END) Dow Jones Newswires
February 07, 2024 11:30 ET (16:30 GMT)
